BBP News and Press, Virtus LifeSci Biotech Products From 05/18/22

Today, we revisit advance wound care name Organogenesis Holdings for the first time since late in 2020. This small cap healthcare concern is already profitable and continues to build out its product portfolio. A full investment analysis follows in the paragraphs below. For f...

Over the years, Exelixis' esteemed management successfully ramped up cabozantinib sales beyond the blockbuster range. Through many ongoing aggressive cabozantinib advancements, you can expect this blockbuster to grow by several more folds in revenue in the next few years. Meanwhil...

With the world facing inflationary and geopolitical hurdles, economic growth is poised to slow. Shares across sectors have been hit hard. Investors in growth stocks must identify companies with the right features to overcome headwinds to earnings. For further details see: ...

Cryoport is not just any biotech company, as it is banking on the booming logistic businesses for the cell/gene therapy sector. Leveraging the powerful merger and acquisition approach, Cryoport has been enjoying leaping top-line growth year-over-year. Despite a temporary setback, ...

Shares of Cue Biopharma have tumbled some 75% since November 2021, as somewhat underwhelming data from slowly developing Phase 1 trials are at fault. The company’s Immuno-STAT platform is a novel approach to immuno-oncology that should reduce risks associated with systemic expo...

Mitapivat got approved for PK deficiency. They have multiple label expansion potential. Current prices are attractively low. For further details see: Agios: Approved Product, Upcoming Catalysts

In a down market, you can pick up the same fundamentally robust companies at a fraction of their intrinsic value. As an orphan disease innovator, BioMarin is enjoying significant and substantial revenue increases from its approved assets. Nevertheless, the company is aggressively ...

Healthcare, Staples, and Utilities continue to outperform as selling intensifies in the growth style. Investor positioning is still light in the space – even after a year of alpha. While absolute valuations have turned somewhat pricey, the defensive supersector shows decent...

DTIL has been lagging due to poor durability data. The company stock has been lagging due to market indifference. I see no prospects here. For further details see: Precision Bio: Another CAR-T Laggard With No Solid Prospects

By selling its only growth asset, Viatris has turned out to be a cigar butt investment that still has many puffs left in it due to its strong free cash flow. Debt remains a concern, but the company continues to deleverage thanks to its strong free cash flow and has accelerated the pro...